VIEWPOINT AND COMMENTARY
Why Should We Care About CARE-HF?
Kenneth A. Ellenbogen, MD, FACC*,*,
Mark A. Wood, MD, FACC* and
Helmut U. Klein, MD, FACC
* Department of Medicine, Virginia Commonwealth University School of Medicine, Richmond, Virginia
Division of Cardiology, University Hospital, Magdeburg, Germany
Manuscript received March 29, 2005;
revised manuscript received July 12, 2005,
accepted July 18, 2005.
* Reprint requests and correspondence: Dr. Kenneth A. Ellenbogen, Medical College of Virginia, P.O. Box 980053, Richmond, Virginia 23298-0053. (Email: kaellenb{at}vcu.edu).
Previous trials of cardiac resynchronization therapy (CRT) have suggested that this therapy can significantly improve functional class and exercise capacity during short-term follow-up. The impact of this therapy on morbidity and mortality has only recently been reported. The Cardiac Resynchronization-Heart Failure (CARE-HF) study has definitively shown that CRT significantly reduces mortality (36%, p < 0.002) in patients with NYHA functional class III and IV heart failure and ventricular dyssynchrony. This study also shows that CRT reverses ventricular remodeling and improves myocardial performance progressively for at least 18 months. In heart failure patients, the CARE-HF and Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) (the earlier major morbidity/mortality trial) studies together show the unequivocal benefit for CRT therapy and CRT therapy with back-up defibrillation to significantly reduce mortality and hospitalization compared with optimal medical therapy. Both studies suggest the benefit of adding the implantable cardiac defibrillator to CRT devices, as over one-third of deaths in the CRT-pacemaker arm of both the COMPANION and CARE-HF studies were sudden.
|
Abbreviations and Acronyms
| | CARE-HF = Cardiac Resynchronization-Heart Failure study | | COMPANION = Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure study | | CRT = cardiac resynchronization therapy | | CRT-D = cardiac resynchronization therapy pacemaker plus back-up defibrillation (implantable cardiac defibrillator) | | CRT-P = cardiac resynchronization therapy pacemaker | | ICD = implantable cardiac defibrillator | | MERIT-HF = Metoprolol Randomized Intervention Trial in Congestive Heart Failure | | NYHA = New York Heart Association | | OPT = optimal pharmacologic therapy |
|
This article has been cited by other articles:
|
|
|
|
 
J. Braun, A. Ciarka, M. I. M. Versteegh, V. Delgado, E. Boersma, H. F. Verwey, M. J. Schalij, J. J. Bax, R. A. E. Dion, N. R. van de Veire, et al.
Cardiac support device, restrictive mitral valve annuloplasty, and optimized medical treatment: A multimodality approach to nonischemic cardiomyopathy
J. Thorac. Cardiovasc. Surg.,
September 1, 2011;
142(3):
e93 - e100.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Albouaini, A. Alkarmi, and D. J. Wright
Cardiac resynchronisation therapy: what a hospital practitioner needs to know?
Postgrad. Med. J.,
January 1, 2010;
86(1011):
12 - 17.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Daubert, C. Leclercq, and P. Mabo
Cardiac resynchronization therapy in combination with implantable cardioverter-defibrillator
Europace,
November 1, 2009;
11(suppl_5):
v87 - v92.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Boveda, E. Marijon, S. Jacob, P. Defaye, J. B. Winter, A. Bulava, D. Gras, J. P. Albenque, N. Combes, D. Pavin, et al.
Incidence and prognostic significance of sustained ventricular tachycardias in heart failure patients implanted with biventricular pacemakers without a back-up defibrillator: results from the prospective, multicentre, Mona Lisa cohort study
Eur. Heart J.,
May 2, 2009;
30(10):
1237 - 1244.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Daubert, C. Leclercq, and P. Mabo
There Is Plenty of Room for Cardiac Resynchronization Therapy Devices Without Back-Up Defibrillators in the Electrical Treatment of Heart Failure
J. Am. Coll. Cardiol.,
December 20, 2005;
46(12):
2204 - 2207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
